-
1
-
-
33748114343
-
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
-
DOI 10.1016/j.jhep.2006.05.013, PII S0168827806002972
-
Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. (Pubitemid 44307383)
-
(2006)
Journal of Hepatology
, vol.45
, Issue.4
, pp. 529-538
-
-
Perz, J.F.1
Armstrong, G.L.2
Farrington, L.A.3
Hutin, Y.J.F.4
Bell, B.P.5
-
2
-
-
33748306328
-
Prevention of mortality from hepatitis B and hepatitis C
-
DOI 10.1016/S0140-6736(06)69347-1, PII S0140673606693471
-
Schiff ER. Prevention of mortality from hepatitis B and hepatitis C. Lancet 2006;368:896-7. (Pubitemid 44331366)
-
(2006)
Lancet
, vol.368
, Issue.9539
, pp. 896-897
-
-
Schiff, E.R.1
-
3
-
-
0025753470
-
Incidence, determinants and significance of delayed clearance of serum HBs AG in chronic hepatitis b virus infection: A prospective study
-
Liaw YF, Sheen IS, Chen TJ, et al. Incidence, determinants and significance of delayed clearance of serum HBs AG in chronic hepatitis B virus infection: A prospective study. Hepatology 1991;13:627-31.
-
(1991)
Hepatology
, vol.13
, pp. 627-631
-
-
Liaw, Y.F.1
Sheen, I.S.2
Chen, T.J.3
-
4
-
-
72949113706
-
Loss of HBs AG antigen during treatment with entecavir or lamivudine in nucleoside-naive HBEAG-positive patients with chronic hepatitis b
-
Gish RG, Chang TT, Lai CL, et al. Loss of HBs AG antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010;17:16-22.
-
(2010)
J Viral Hepat
, vol.17
, pp. 16-22
-
-
Gish, R.G.1
Chang, T.T.2
Lai, C.L.3
-
5
-
-
75449107726
-
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
-
Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
-
(2010)
Hepatology
, vol.51
, pp. 422-430
-
-
Chang, T.T.1
Lai, C.L.2
Kew, Y.S.3
-
6
-
-
84865487986
-
Sustained responses and loss of HBs AG in HBEAG-negative patients with chronic hepatitis b who stop long- Term treatment with adefovir
-
Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBs AG in HBeAg-negative patients with chronic hepatitis B who stop long- Term treatment with adefovir. Gastroenterology 2012;143:629-36.
-
(2012)
Gastroenterology
, vol.143
, pp. 629-636
-
-
Hadziyannis, S.J.1
Sevastianos, V.2
Rapti, I.3
-
7
-
-
84873726484
-
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study
-
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013;381:468-75.
-
(2013)
Lancet
, vol.381
, pp. 468-475
-
-
Marcellin, P.1
Gane, E.2
Buti, M.3
-
8
-
-
48549107919
-
Sustained HBEAG and HBs AG loss after long- Term follow-up of HBEAG-positive patients treated with peginterferon alpha-2b
-
Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBs AG loss after long- Term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-67.
-
(2008)
Gastroenterology
, vol.135
, pp. 459-467
-
-
Buster, E.H.1
Flink, H.J.2
Cakaloglu, Y.3
-
9
-
-
67349168493
-
High rates of HBs AG seroconversion in HBEAG-positive chronic hepatitis B patients responding to interferon: A long- Term follow-up study
-
Moucari R, Korevaar A, Lada O, et al. High rates of HBs AG seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long- Term follow-up study. J Hepatol 2009;50:1084-92.
-
(2009)
J Hepatol
, vol.50
, pp. 1084-1092
-
-
Moucari, R.1
Korevaar, A.2
Lada, O.3
-
10
-
-
0001731999
-
Delayed clearance of serum HBsAG in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis
-
DOI 10.1111/j.1572-0241.1998.00272.x, PII S0002927098001531
-
Fattovich G, Giustina G, Sanchez- Tapias J, et al. Delayed clearance of serum HBs AG in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998;93:896-900. (Pubitemid 29076972)
-
(1998)
American Journal of Gastroenterology
, vol.93
, Issue.6
, pp. 896-900
-
-
Fattovich, G.1
Giustina, G.2
Sanchez-Tapias, J.3
Quero, C.4
Mas, A.5
Olivotto, P.G.6
Solinas, A.7
Almasio, P.8
Hadziyannis, S.9
Degos, F.10
De Moura, M.C.11
Krogsgaard, K.12
Pantalena, M.13
Realdi, G.14
Corrocher, R.15
Schalm, S.W.16
Craxi, A.17
Delarocque, E.18
Savvas, S.19
Cossu, P.20
Tocco, A.21
Olsen, J.22
Christensen, E.23
Rocha, P.24
more..
-
11
-
-
34248679355
-
HBs AG seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long- Term follow-up
-
Chu CM, Liaw YF. HBs AG seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long- Term follow-up. Hepatology 2007;45:1187-92.
-
(2007)
Hepatology
, vol.45
, pp. 1187-1192
-
-
Chu, C.M.1
Liaw, Y.F.2
-
12
-
-
53049107213
-
HBs AG seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma
-
Yuen MF, Wong DK, Fung J, et al. HBs AG Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
-
(2008)
Gastroenterology
, vol.135
, pp. 1192-1199
-
-
Yuen, M.F.1
Wong, D.K.2
Fung, J.3
-
13
-
-
70349240414
-
Chronic hepatitis B: Update 2009
-
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
-
(2009)
Hepatology
, vol.50
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
14
-
-
84862664371
-
EASL clinical practice guidelines: Management of chronic hepatitis b virus infection
-
European Association for the Study of the Liver
-
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
-
(2012)
J Hepatol
, vol.57
, pp. 167-185
-
-
-
15
-
-
33847028842
-
Identification of a hepatitis B virus S gene mutant in lamivudine- Treated patients experiencing HBs AG seroclearance
-
Hsu CW, Yeh CT, Chang ML, et al. Identification of a hepatitis B virus S gene mutant in lamivudine- Treated patients experiencing HBs AG seroclearance. Gastroenterology 2007;132:543-50.
-
(2007)
Gastroenterology
, vol.132
, pp. 543-550
-
-
Hsu, C.W.1
Yeh, C.T.2
Chang, M.L.3
-
16
-
-
11144357081
-
Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments
-
DOI 10.1016/j.jhep.2004.01.006, PII S0168827804000170
-
Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837-44. (Pubitemid 38507366)
-
(2004)
Journal of Hepatology
, vol.40
, Issue.5
, pp. 837-844
-
-
Hong, S.P.1
Kim, N.K.2
Hwang, S.G.3
Chung, H.J.4
Kim, S.5
Han, J.H.6
Kim, H.T.7
Rim, K.S.8
Kang, M.S.9
Yoo, W.10
Kim, S.-O.11
-
17
-
-
27744494442
-
Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea
-
Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005;20:816-20.
-
(2005)
J Korean Med Sci
, vol.20
, pp. 816-820
-
-
Bae, S.H.1
Yoon, S.K.2
Jang, J.W.3
-
19
-
-
2542516261
-
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects
-
DOI 10.1002/hep.20240
-
Yuen MF, Wong DK, Sablon E, et al. HBs AG seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004;39:1694-701. (Pubitemid 38702671)
-
(2004)
Hepatology
, vol.39
, Issue.6
, pp. 1694-1701
-
-
Yuen, M.-F.1
Wong, D.K.-H.2
Sablon, E.3
Tse, E.4
Ng, I.O.-L.5
Yuan, H.-J.6
Siu, C.-W.7
Sander, T.J.8
Bourne, E.J.9
Hall, J.G.10
Condreay, L.D.11
Lai, C.-L.12
-
20
-
-
0142244873
-
Determinants for sustained HBEAG response to lamivudine therapy
-
Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267-73.
-
(2003)
Hepatology
, vol.38
, pp. 1267-1273
-
-
Chien, R.N.1
Yeh, C.T.2
Tsai, S.L.3
-
21
-
-
4644219526
-
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma
-
DOI 10.1136/gut.2003.033324
-
Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53:1494-8. (Pubitemid 39265273)
-
(2004)
Gut
, vol.53
, Issue.10
, pp. 1494-1498
-
-
Chan, H.L.-Y.1
Hui, A.Y.2
Wong, M.L.3
Tse, A.M.-L.4
Hung, L.C.-T.5
Wong, V.W.-S.6
Sung, J.J.-Y.7
-
22
-
-
51049117284
-
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma
-
Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 1134-1143
-
-
Yang, H.I.1
Yeh, S.H.2
Chen, P.J.3
-
23
-
-
13844322073
-
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men
-
Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005;97:265-72.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 265-272
-
-
Yu, M.W.1
Yeh, S.H.2
Chen, P.J.3
-
24
-
-
30944449596
-
Long- Term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis b
-
Arase Y, Ikeda K, Suzuki F, et al. Long- Term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.9-16.
-
(2006)
Am J Med
, vol.119
, Issue.71
, pp. 9-16
-
-
Arase, Y.1
Ikeda, K.2
Suzuki, F.3
-
25
-
-
0036789020
-
Prognosis following spontaneous HBs AG seroclearance in chronic hepatitis b patients with or without concurrent infection
-
Chen YC, Sheen IS, Chu CM, et al. Prognosis following spontaneous HBs AG seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002;123:1084-9.
-
(2002)
Gastroenterology
, vol.123
, pp. 1084-1089
-
-
Chen, Y.C.1
Sheen, I.S.2
Chu, C.M.3
-
26
-
-
77953441846
-
Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy
-
Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010;15:471-5.
-
(2010)
Antivir Ther
, vol.15
, pp. 471-475
-
-
Yeh, C.T.1
-
27
-
-
0033754947
-
Evolution of hepatitis B virus polymerase gene mutations in hepatitis b e antigen-negative patients receiving lamivudine therapy
-
Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-53.
-
(2000)
Hepatology
, vol.32
, pp. 1145-1153
-
-
Lok, A.S.1
Hussain, M.2
Cursano, C.3
-
28
-
-
0036038911
-
Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene
-
DOI 10.1006/viro.2002.1448
-
Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002;299:88-99. (Pubitemid 35007514)
-
(2002)
Virology
, vol.299
, Issue.1
, pp. 88-99
-
-
Torresi, J.1
Earnest-Silveira, L.2
Civitico, G.3
Walters, T.E.4
Lewin, S.R.5
Fyfe, J.6
Locarnini, S.A.7
Manns, M.8
Trautwein, C.9
Bock, T.C.10
-
29
-
-
33745619248
-
Hepatitis B virus mutations associated with antiviral therapy
-
Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006;78(Suppl 1):52-5.
-
(2006)
J Med Virol
, vol.78
, Issue.SUPPL. 1
, pp. 52-55
-
-
Bartholomeusz, A.1
Locarnini, S.2
-
30
-
-
0242487671
-
Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen
-
Yeh CT, Chang MH, Lai HY, et al. Identification of a novel pre-S2 mutation in a subgroup of chronic carriers with spontaneous clearance of hepatitis B virus surface antigen. J Gastroenterol Hepatol 2003;18:1129-38.
-
(2003)
J Gastroenterol Hepatol
, vol.18
, pp. 1129-1138
-
-
Yeh, C.T.1
Chang, M.H.2
Lai, H.Y.3
-
31
-
-
47249117068
-
Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant
-
Sloan RD, Ijaz S, Moore PL, et al. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008;13:439-47. (Pubitemid 352016737)
-
(2008)
Antiviral Therapy
, vol.13
, Issue.3
, pp. 439-447
-
-
Sloan, R.D.1
Ijaz, S.2
Moore, P.L.3
Harrison, T.J.4
Teo, C.-G.5
Tedder, R.S.6
-
32
-
-
77950969605
-
Comparison of the technical and clinical performance of the elecsys HBs AG II assay with the architect, Ax Sym, and advia centaur HB SAG screening assays
-
Louisirirotchanakul S, Khupulsup K, Akraekthalin S, et al. Comparison of the technical and clinical performance of the Elecsys HBs AG II assay with the Architect, AxSym, and Advia Centaur HBs AG screening assays. J Med Virol 2010;82:755-62.
-
(2010)
J Med Virol
, vol.82
, pp. 755-762
-
-
Louisirirotchanakul, S.1
Khupulsup, K.2
Akraekthalin, S.3
-
33
-
-
34247173078
-
Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
-
DOI 10.1159/000098958
-
Arase Y, Suzuki F, Suzuki Y, et al. Long- Term presence of HBV in the sera of chronic hepatitis B patients with HBs AG seroclearance. Intervirology 2007;50:161-5. (Pubitemid 46597275)
-
(2007)
Intervirology
, vol.50
, Issue.3
, pp. 161-165
-
-
Arase, Y.1
Suzuki, F.2
Suzuki, Y.3
Saitoh, S.4
Kobayashi, M.5
Akuta, N.6
Someya, T.7
Hosaka, T.8
Sezaki, H.9
Sato, J.10
Kobayashi, M.11
Ikeda, K.12
Kumada, H.13
-
34
-
-
84555209282
-
Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis b surface antigen seroclearance in hepatitis B carriers
-
Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis 2012;54:88-90.
-
(2012)
Clin Infect Dis
, vol.54
, pp. 88-90
-
-
Chu, C.M.1
Liaw, Y.F.2
-
35
-
-
79960124298
-
Serum HBs AG decline during long- Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBs AG loss
-
Zoutendijk R, Hansen BE, van Vuuren AJ, et al. Serum HBs AG decline during long- Term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBs AG loss. J Infect Dis 2011;204:415-18.
-
(2011)
J Infect Dis
, vol.204
, pp. 415-418
-
-
Zoutendijk, R.1
Hansen, B.E.2
Van Vuuren, A.J.3
-
36
-
-
80054724912
-
Hepatitis B surface antigen quantification: Why and how to use it in 2011- A core group report
-
Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011- A core group report. J Hepatol 2011;55:1121-31.
-
(2011)
J Hepatol
, vol.55
, pp. 1121-1131
-
-
Chan, H.L.1
Thompson, A.2
Martinot-Peignoux, M.3
-
37
-
-
84866705034
-
Restored function of HBV-specific T cells after long- Term effective therapy with nucleos(t)ide analogues
-
Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long- Term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-73.
-
(2012)
Gastroenterology
, vol.143
, pp. 963-973
-
-
Boni, C.1
Laccabue, D.2
Lampertico, P.3
-
38
-
-
12444252951
-
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B
-
DOI 10.1016/S0168-8278(03)00292-7
-
Boni C, Penna A, Bertoletti A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605. (Pubitemid 37204661)
-
(2003)
Journal of Hepatology
, vol.39
, Issue.4
, pp. 595-605
-
-
Boni, C.1
Penna, A.2
Bertoletti, A.3
Lamonaca, V.4
Rapti, I.5
Missale, G.6
Pilli, M.7
Urbani, S.8
Cavalli, A.9
Cerioni, S.10
Panebianco, R.11
Jenkins, J.12
Ferrari, C.13
-
39
-
-
80052957789
-
Hepatitis b surface antigen (HBs AG) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBs AG loss during treatment with nucleoside/nucleotide analogues
-
Jaroszewicz J, Ho H, Markova A, et al. Hepatitis B surface antigen (HBs AG) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBs AG loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011;16:915-24.
-
(2011)
Antivir Ther
, vol.16
, pp. 915-924
-
-
Jaroszewicz, J.1
Ho, H.2
Markova, A.3
-
40
-
-
78650477355
-
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
-
Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-43.
-
(2011)
Gastroenterology
, vol.140
, pp. 132-143
-
-
Heathcote, E.J.1
Marcellin, P.2
Buti, M.3
-
41
-
-
84883212438
-
Reduction of hepatitis b surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy
-
Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013;58:923-31.
-
(2013)
Hepatology
, vol.58
, pp. 923-931
-
-
Seto, W.K.1
Wong, D.K.2
Fung, J.3
-
42
-
-
84904063753
-
Seroclearance rate of hepatitis b surface antigen in 2, 112 patients with chronic hepatitis in Japan during long- Term follow-up
-
Epub ahead of print
-
Kobayashi M, Hosaka T, Suzuki F, et al. Seroclearance rate of hepatitis B surface antigen in 2, 112 patients with chronic hepatitis in Japan during long- Term follow-up. J Gastroenterol 2013:Epub ahead of print.
-
(2013)
J Gastroenterol
-
-
Kobayashi, M.1
Hosaka, T.2
Suzuki, F.3
-
43
-
-
84861185904
-
HBV DNA suppression and HBs AG clearance in HBEAG negative chronic hepatitis B patients on lamivudine therapy for over 5 years
-
Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppression and HBs AG clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8.
-
(2012)
J Hepatol
, vol.56
, pp. 1254-1258
-
-
Fasano, M.1
Lampertico, P.2
Marzano, A.3
-
44
-
-
77956592924
-
Kinetics of hepatitis b surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
-
Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010;52:1611-20.
-
(2010)
Hepatology
, vol.52
, pp. 1611-1620
-
-
Wursthorn, K.1
Jung, M.2
Riva, A.3
-
45
-
-
65449123444
-
Early serum HBs AG drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBEAG-negative patients
-
Moucari R, Mackiewicz V, Lada O, et al. Early serum HBs AG drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.
-
(2009)
Hepatology
, vol.49
, pp. 1151-1157
-
-
Moucari, R.1
Mackiewicz, V.2
Lada, O.3
-
46
-
-
83455163799
-
Prediction of off- Treatment response to lamivudine by serum hepatitis b surface antigen quantification in hepatitis B e antigen-negative patients
-
Chan HL, Wong GL, Chim AM, et al. Prediction of off- Treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011;16:1249-57.
-
(2011)
Antivir Ther
, vol.16
, pp. 1249-1257
-
-
Chan, H.L.1
Wong, G.L.2
Chim, A.M.3
-
47
-
-
84876286013
-
A predictive scoring system for the seroclearance of HBs AG in HBEAG-seronegative chronic hepatitis B patients with genotype b or c infection
-
Liu J, Lee MH, Batrla-Utermann R, et al. A predictive scoring system for the seroclearance of HBs AG in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol 2013;58:853-60.
-
(2013)
J Hepatol
, vol.58
, pp. 853-860
-
-
Liu, J.1
Lee, M.H.2
Batrla-Utermann, R.3
-
48
-
-
84865535075
-
A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis b surface antigen seroclearance
-
Seto WK, Wong DK, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012;56:812-19.
-
(2012)
Hepatology
, vol.56
, pp. 812-819
-
-
Seto, W.K.1
Wong, D.K.2
Fung, J.3
-
49
-
-
84984571825
-
Determinants of spontaneous surface antigen loss in hepatitis b e antigen-negative patients with a low viral load
-
Tseng TC, Liu CJ, Yang HC, et al. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2011;55:68-76.
-
(2011)
Hepatology
, vol.55
, pp. 68-76
-
-
Tseng, T.C.1
Liu, C.J.2
Yang, H.C.3
-
50
-
-
84880939335
-
Long- Term hepatitis b surface antigen (HBs AG) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely
-
Chevaliez S, Hezode C, Bahrami S, et al. Long- Term hepatitis B surface antigen (HBs AG) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676-83.
-
(2013)
J Hepatol
, vol.58
, pp. 676-683
-
-
Chevaliez, S.1
Hezode, C.2
Bahrami, S.3
|